MIRA
INFORM REPORT
|
Report Date : |
17.01.2008 |
IDENTIFICATION
DETAILS
|
Name : |
MEDIATE PHARMACEUTICALS PRIVATE LIMITED |
|
|
|
|
Registered Office : |
Plot # 150 -
151, Sector 24, Korangi Industrial Area, Karachi |
|
|
|
|
Country : |
Pakistan |
|
|
|
|
Date of Incorporation : |
2004 |
|
|
|
|
Com. Reg. No.: |
0046717 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacture & Marketing of
Pharmaceutical Products |
RATING &
COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
Status : |
Small Company |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
Business Name
MEDIATE
PHARMACEUTICALS (PRIVATE) LIMITED
Full Address
Registered Address & Factory
Plot # 150 - 151, Sector
24, Korangi Industrial Area, Karachi, Pakistan
Tel 92 (21) 5074746, 5074747
Fax 92 (21) 5074196
Website www.mediatepharma.com.pk
Short Description Of
Business
Nature of Business Manufacture & Marketing of Pharmaceutical
Products
Year Established 2004
Registration # 0046717
Branches
None
Auditors
M/s Salauddin & Company
(Chartered
Accountants)
514, 5th Floor, Madina
City Mall, Abdullah Haroon Road, Karachi, Pakistan
Legal Status
Subject Company was established as a Private
Limited Company in 2004
Authorized Capital
Rs. 10,000,000/- divided into 100,000 shares of Rs. 100/- each
Issued & Paid up
Capital
Rs. 10,000,000/- divided into 100,000 shares of Rs. 100/- each
Details of Chief Executive/ Directors
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Mr. Khalid Hussain Mrs. Fahmida Khalid Mr. Nasrullah Shaikh Mr. Imtiaz Nasar Shaikh Mrs. Rozina Shaikh |
Pakistani Pakistani Pakistani Pakistani Pakistani |
B-8, Prince
Complex, Clifton, Karachi B-8, Prince
Complex, Clifton, Karachi Syed Ali Akber
Shah Mehar, Dadu Syed Ali Akber
Shah Mehar, Dadu Flat 1, Lalazar
Appartments, Block-2, P.E.C.H.S., Karachi |
Business Business Business Business Business |
Chief Executive Director Director Director Director |
Shareholders
|
Names |
No. of Shares |
|
Mr. Khalid Hussain Mrs. Fahmida Khalid Mr. Nasrullah Shaikh Mr. Imtiaz Nasar Shaikh Mrs. Rozina Shaikh |
35,000 30,000 15,000 15,000 5,000 |
Associates
SUBSIDIARY
None
ASSOCIATED COMPANIES
Prema Products, Pakistan
Products / Services
Manufacture & marketing of Pharmaceutical Products
Number of Employees
87
Trade Suppliers (Foreign)
VASUDHA PHARMA, INDIA.
NOSCH LABS, INDIA.
MURLI KRISHNA (PVT) LIMITED, INDIA.
ZHUHAI UNITED LABORATORIES
CO.LTD, CHINA.
Annual Production Volume
The capacity and production of the company’s plant
is indeterminable as it involves varying processes of manufacture
Annual Sales Volume
|
Year |
In Pak Rupees |
|
2006 - 2007 |
Not ascertained as the subject is recently started its commercial
production |
Customers
Company is in the process
of making its distributors in all major cities of Pakistan
Bankers
PICIC Commercial
Bank Limited, Pakistan.
(Mortgage obtained
PKR 40,000,000/-)
Soneri Bank
Limited, Pakistan.
Faysal Bank Limited, Pakistan.
Memberships
·
Pakistan Pharmaceutical Manufacturers Association.(PPMA)
- Korangi Association of Trade & Industry.(KATI)
Foreign Exchange
Rates
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 62.50 |
|
UK Pound |
1 |
Rs. 122.30 |
|
Euro |
1 |
Rs.
92.40 |
Comments
Subject Company was established in 2004 and
is engaged in manufacture & marketing of Pharmaceutical Products. Overall
reputation is normal. Trade relations are reported as fair. The Company can be
considered for normal business dealings at usual trade terms & conditions.
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)